IL22

Across TCGA pan-cancer cohorts, IL22 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated IL22 data layer compared with 4 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IL22 RNA is associated with better overall survival. In most high-consensus cancer types, elevated IL22 expression acts as an unfavorable survival marker, although some lineages such as BLCA and LUAD show a favorable association.

BLCA, KIRC, and LUAD are the cancer types where IL22 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.779	0.556	<.001	131	view →
KIRC	OS	Median	All	0.494	0.695	<.001	88	view →
LUAD	OS	Median	II,III,IV	0.760	0.478	<.001	80	view →
STAD	DFS	Tertile	II,III,IV	0.554	0.735	<.001	59	view →
LUSC	OS	Tertile	IV	0.057	0.786	.008	36	view →
DLBC	DFS	Quartile	All	0.551	0.921	.005	31	view →
ACC	OS	Tertile	All	0.627	0.895	.007	18	view →
MESO	OS	Median	All	0.739	0.285	.002	18	view →
SKCM	DFS	Quartile	III,IV	0.670	0.432	.009	15	view →
THYM	DFS	Tertile	All	0.396	0.811	<.001	15	view →
OV	OS	Tertile	III,IV	0.395	0.308	.034	12	view →
THCA	OS	Tertile	II,III,IV	0.939	0.986	.006	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

IL22–BLCA (OS)

Open the BLCA breakdown →